Pharmaceutics (Jul 2023)

Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy

  • Joshua Hurwitz,
  • Lucy Roxana Haggstrom,
  • Elgene Lim

DOI
https://doi.org/10.3390/pharmaceutics15082017
Journal volume & issue
Vol. 15, no. 8
p. 2017

Abstract

Read online

Antibody–drug conjugates (ADCs) have provided new therapeutic options and significant promise for patients with cancer, particularly where existing treatments are limited. Substantial effort in ADC development is underway globally, with 13 ADCs currently approved and many more in development. The therapeutic benefits of ADCs leverage the ability to selectively target cancer cells through antibody binding, resultant relative sparing of non-malignant tissues, and the targeted delivery of a cytotoxic payload. Consequently, this drug class has demonstrated activity in multiple malignancies refractory to standard therapeutic options. Despite this, limitations exist, including narrow therapeutic windows, unique toxicity profiles, development of therapeutic resistance, and appropriate biomarker selection. This review will describe the development of ADCs, their mechanisms of action, pivotal trials, and approved indications and identify common themes. Current challenges and opportunities will be discussed for this drug class in cancer therapeutics at a time when significant developments in antibody therapies, immunotherapy, and targeted agents are occurring.

Keywords